Citius Pharmaceuticals' LYMPHIR Added To NCCN Clinical Practice Guidelines With Category 2A Recommendation For Treatment Of Cutaneous T-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Citius Pharmaceuticals' drug LYMPHIR has been added to the NCCN Clinical Practice Guidelines with a Category 2A recommendation for treating Cutaneous T-Cell Lymphoma.
September 05, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citius Pharmaceuticals' LYMPHIR has been included in the NCCN Clinical Practice Guidelines with a Category 2A recommendation, which could enhance its credibility and adoption in treating Cutaneous T-Cell Lymphoma.
The inclusion of LYMPHIR in the NCCN Guidelines with a Category 2A recommendation is a significant endorsement that could lead to increased usage and sales, positively impacting Citius Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100